Inverse Anderson transitions, where the flat-band localization is destroyed by disorder, have been wildly investigated in quantum and classical systems in the presence of Abelian gauge fields. Here, we report the first investigation on inverse Anderson transitions in the system with non-Abelian gauge fields. It is found that pseudospin-dependent localized and delocalized eigenstates coexist in the disordered non-Abelian Aharonov-Bohm cage, making inverse Anderson transitions depend on the relative phase of two internal pseudospins. Such an exotic phenomenon induced by the interplay between non-Abelian gauge fields and disorder has no Abelian analogy. Furthermore, we theoretically design and experimentally fabricate non-Abelian Aharonov-Bohm topolectrical circuits to observe the non-Abelian inverse Anderson transition. Through the direct measurements of frequency-dependent impedance responses and voltage dynamics, the pseudospin-dependent non-Abelian inverse Anderson transitions are observed. Our results establish the connection between inverse Anderson transitions and non-Abelian gauge fields, and thus comprise a new insight on the fundamental aspects of localization in disordered non-Abelian flat-band systems.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1103/PhysRevLett.130.206401 | DOI Listing |
Diabetes Obes Metab
January 2025
School of Health and Wellbeing, University of Glasgow, Glasgow, UK.
Aims: Glucagon-like peptide 1 receptor agonists (GLP1RA), used to treat type 2 diabetes and obesity, have been associated with off-target behavioural effects. We systematically assessed genetic variation in the GLP1R locus for impact on mental ill-health (MIH) and cardiometabolic phenotypes across diverse populations within UK Biobank.
Materials And Methods: All genetic variants with minor allele frequency >1% in the GLP1R locus were investigated for associations with MIH phenotypes and cardiometabolic phenotypes.
Cancer Causes Control
January 2025
Surveillance and Health Equity Science, American Cancer Society, Kennesaw, GA, USA.
Purpose: Oncological treatments, such as radiotherapy, which requires consistent electricity, the presence of specialized clinical teams, and daily patient access to treatment facilities, are frequently disrupted by extreme weather events, posing several health hazards to patients. This study explores the association between declared wildfire disasters during radiotherapy and overall survival among patients with non-small cell lung cancer (NSCLC).
Methods: The study population consisted of 202,935 adults with inoperable Stage III NSCLC, who initiated radiotherapy from 2004 through 2019.
Physiol Rep
January 2025
Clinical and Experimental Therapeutics, University of Georgia, Augusta, Georgia, USA.
Cancer is a complex disease with profound societal and economic impacts, especially in metastatic cases where treatment challenges arise due to the absence of reliable biomarkers and effective therapies. While P21-activated kinases (PAKs) play a key role in cancer progression, their potential as predictive markers for metastasis and therapeutic targets has not been fully explored. We hypothesized that genetic alterations in PAK isoforms could be linked to reduced overall patient survival.
View Article and Find Full Text PDFESMO Open
January 2025
UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, USA.
Background: Randomized controlled trials have shown inconsistent overall survival (OS) benefit among the three cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) as first-line (1L) treatment of patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). Several real-world studies compared CDK4/6i effectiveness, with inconsistent findings. This study compared overall survival (OS) of patients with HR+/HER2- mBC receiving 1L palbociclib, ribociclib, or abemaciclib, in combination with an aromatase inhibitor (AI), in US clinical practice.
View Article and Find Full Text PDFThe BMT CTN 1703 phase III trial confirmed that graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF) results in superior GVHD-free, relapse-free survival (GRFS) compared with Tac/methotrexate (MTX) prophylaxis. This companion study assesses the effect of these regimens on patient-reported outcomes (PROs). Using the Lee Chronic GVHD Symptom Score and PROMIS subscales (physical function, GI symptoms, social role satisfaction) as primary end points and hemorrhagic cystitis symptoms and Lee subscales as secondary end points, responses from English and Spanish speakers were analyzed at baseline and days 100, 180, and 365 after transplant.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!